{"id":61140,"date":"2025-04-24T04:06:15","date_gmt":"2025-04-24T02:06:15","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/ono-pharma-announces-an-oral-presentation-on-phase-2-data-for-tirabrutinib-and-a-poster-session-on-ono-4578-ep4-antagonist-at-the-american-society-of-clinical-oncology-asco-annual-meeting\/"},"modified":"2025-04-24T04:06:15","modified_gmt":"2025-04-24T02:06:15","slug":"ono-pharma-announces-an-oral-presentation-on-phase-2-data-for-tirabrutinib-and-a-poster-session-on-ono-4578-ep4-antagonist-at-the-american-society-of-clinical-oncology-asco-annual-meeting","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/ono-pharma-announces-an-oral-presentation-on-phase-2-data-for-tirabrutinib-and-a-poster-session-on-ono-4578-ep4-antagonist-at-the-american-society-of-clinical-oncology-asco-annual-meeting\/","title":{"rendered":"Ono Pharma Announces an Oral Presentation on Phase 2 Data for Tirabrutinib and a Poster Session on ONO-4578 (EP4 Antagonist) at the American Society of Clinical Oncology (ASCO) Annual Meeting"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\nPositive data from the Phase 2 PROSPECT Study of tirabrutinib in U.S. patients with relapsed or refractory primary central nervous system lymphoma (PCNSL) will be presented in a rapid oral session.\n<\/li>\n<li>\nData on the neoadjuvant ONO-4578 (EP4 antagonist) in combination with nivolumab for rectal cancer will be presented in a poster session.\n<\/li>\n<\/ul>\n<p>OSAKA, Japan&#8211;(BUSINESS WIRE)&#8211;Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; \u201cONO\u201d) announced that it will present positive results from the Phase 2 PROSPECT study of tirabrutinib (ONO-4059) for the treatment of relapsed or refractory primary central nervous system lymphoma during an oral presentation at the <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fconferences.asco.org%2Fam%2Fattend&amp;esheet=54241717&amp;newsitemid=20250423948442&amp;lan=en-US&amp;anchor=Annual+Meeting+of+the+American+Society+of+Clinical+Oncology+%28ASCO%29&amp;index=1&amp;md5=4f94eb43e45113f1123e8332d4cb332e\" rel=\"nofollow\" shape=\"rect\">Annual Meeting of the American Society of Clinical Oncology (ASCO)<\/a> being held May 30 to June 3, 2025, in Chicago, Illinois. The company will also present data on ONO-4578, an investigational EP4 antagonist, for the treatment of locally advanced resectable rectal cancer, during a poster presentation.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20250423948442\/en\/2406587\/5\/ONO_Logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250423948442\/en\/2406587\/22\/ONO_Logo.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20250423948442\/en\/2406587\/5\/ONO_Logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250423948442\/en\/2406587\/21\/ONO_Logo.jpg\"><\/a><\/p>\n<p>\n&#8220;We are fully committed to developing innovative drugs for cancer patients. This announcement is an important step forward in demonstrating that we can potentially provide new value to patients,\u201d said Tatsuya Okamoto, Corporate Officer \/ Executive Director, Clinical Development at ONO. \u201cWe aim to offer new treatment options in cancer care globally and contribute to improving patients&#8217; quality of life.&#8221;\n<\/p>\n<p>\nDetails for both studies and data to be presented are as follows:\n<\/p>\n<p>\n<b><span class=\"bwuline\">Tirabrutinib (ONO-4059)<br \/>\n<br \/><\/span><\/b>Abstract Title: Tirabrutinib for the treatment of relapsed or refractory primary central nervous system lymphoma: Efficacy and safety from the phase II PROSPECT study.<br \/>\n<br \/>Abstract Submission ID: 487376<br \/>\n<br \/>Session Type and Title: Rapid Oral Abstract \u2013 Central Nervous System Tumors<br \/>\n<br \/>Session Date and Time: May 31, 2025, 3:00-4:30 PM CDT<br \/>\n<br \/>Presenter: Lakshmi Nayak, MD, Dana-Farber Cancer Institute\n<\/p>\n<p>\n<b><span class=\"bwuline\">ONO-4578<br \/>\n<br \/><\/span><\/b>Abstract Title: Neoadjuvant ONO-4578, an EP4 antagonist, in combination with nivolumab after chemoradiation therapy in locally advanced resectable rectal cancer.<br \/>\n<br \/>Session Type and Title: Poster Session Gastrointestinal Cancer \u2013 Colorectal and Anal<br \/>\n<br \/>Abstract Number for Publication: 3588<br \/>\n<br \/>Poster Board: 257<br \/>\n<br \/>Session Date and Time: May 31, 2025, 9:00 AM-12:00 PM CDT<br \/>\n<br \/>Presenter: Yusuke Takahashi, Lower Gastrointestinal Surgery, National Hospital Organization Osaka National Hospital\n<\/p>\n<p>\n<b><span class=\"bwuline\">About Ono Pharmaceutical Co., Ltd<br \/>\n<br \/><\/span><\/b>Ono Pharmaceutical Co., Ltd. delivers innovative therapies for patients worldwide. Upholding its philosophy of \u201cDedicated to the Fight against Disease and Pain,\u201d Ono targets areas with unmet medical needs including oncology, immunology, and neurology, and fosters partnerships with academic and biotech organizations to accelerate drug discovery. Through its affiliate, Deciphera Pharmaceuticals, Ono is accelerating clinical development and commercial operations in the US and Europe to drive global business expansion and further its commitment to patient care. For more information, please visit the company&#8217;s website at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ono-pharma.com%2Fen&amp;esheet=54241717&amp;newsitemid=20250423948442&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.ono-pharma.com%2Fen&amp;index=2&amp;md5=f35be33db56aa5d4b9e7ef1755a4cef1\" rel=\"nofollow\" shape=\"rect\">https:\/\/www.ono-pharma.com\/en<\/a>.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nOno Pharmaceutical Co., Ltd.<br \/>\n<br \/>Corporate Communications<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;i&#108;&#x74;o&#58;&#x70;u&#98;&#x6c;i&#99;&#x5f;&#114;&#x65;&#x6c;&#97;&#x74;&#x69;&#111;&#x6e;s&#64;&#x6f;n&#111;&#x2d;p&#104;&#x61;r&#109;&#x61;&#46;&#x63;&#x6f;&#109;\" rel=\"nofollow\" shape=\"rect\">pub&#108;&#105;&#99;&#x5f;&#x72;&#x65;&#x6c;&#x61;&#x74;ion&#115;&#64;&#111;&#110;&#x6f;&#x2d;&#x70;&#x68;&#x61;&#x72;ma&#46;&#99;&#111;&#109;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Positive data from the Phase 2 PROSPECT Study of tirabrutinib in U.S. patients with relapsed or refractory primary central nervous system lymphoma (PCNSL) will be presented in a rapid oral session. Data on the neoadjuvant ONO-4578 (EP4 antagonist) in combination with nivolumab for rectal cancer will be presented in a poster session. OSAKA, Japan&#8211;(BUSINESS WIRE)&#8211;Ono &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/ono-pharma-announces-an-oral-presentation-on-phase-2-data-for-tirabrutinib-and-a-poster-session-on-ono-4578-ep4-antagonist-at-the-american-society-of-clinical-oncology-asco-annual-meeting\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-61140","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ono Pharma Announces an Oral Presentation on Phase 2 Data for Tirabrutinib and a Poster Session on ONO-4578 (EP4 Antagonist) at the American Society of Clinical Oncology (ASCO) Annual Meeting - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/ono-pharma-announces-an-oral-presentation-on-phase-2-data-for-tirabrutinib-and-a-poster-session-on-ono-4578-ep4-antagonist-at-the-american-society-of-clinical-oncology-asco-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ono Pharma Announces an Oral Presentation on Phase 2 Data for Tirabrutinib and a Poster Session on ONO-4578 (EP4 Antagonist) at the American Society of Clinical Oncology (ASCO) Annual Meeting - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Positive data from the Phase 2 PROSPECT Study of tirabrutinib in U.S. patients with relapsed or refractory primary central nervous system lymphoma (PCNSL) will be presented in a rapid oral session. Data on the neoadjuvant ONO-4578 (EP4 antagonist) in combination with nivolumab for rectal cancer will be presented in a poster session. OSAKA, Japan&#8211;(BUSINESS WIRE)&#8211;Ono ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/ono-pharma-announces-an-oral-presentation-on-phase-2-data-for-tirabrutinib-and-a-poster-session-on-ono-4578-ep4-antagonist-at-the-american-society-of-clinical-oncology-asco-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-24T02:06:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250423948442\/en\/2406587\/22\/ONO_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ono-pharma-announces-an-oral-presentation-on-phase-2-data-for-tirabrutinib-and-a-poster-session-on-ono-4578-ep4-antagonist-at-the-american-society-of-clinical-oncology-asco-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ono-pharma-announces-an-oral-presentation-on-phase-2-data-for-tirabrutinib-and-a-poster-session-on-ono-4578-ep4-antagonist-at-the-american-society-of-clinical-oncology-asco-annual-meeting\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Ono Pharma Announces an Oral Presentation on Phase 2 Data for Tirabrutinib and a Poster Session on ONO-4578 (EP4 Antagonist) at the American Society of Clinical Oncology (ASCO) Annual Meeting\",\"datePublished\":\"2025-04-24T02:06:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ono-pharma-announces-an-oral-presentation-on-phase-2-data-for-tirabrutinib-and-a-poster-session-on-ono-4578-ep4-antagonist-at-the-american-society-of-clinical-oncology-asco-annual-meeting\\\/\"},\"wordCount\":465,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ono-pharma-announces-an-oral-presentation-on-phase-2-data-for-tirabrutinib-and-a-poster-session-on-ono-4578-ep4-antagonist-at-the-american-society-of-clinical-oncology-asco-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250423948442\\\/en\\\/2406587\\\/22\\\/ONO_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ono-pharma-announces-an-oral-presentation-on-phase-2-data-for-tirabrutinib-and-a-poster-session-on-ono-4578-ep4-antagonist-at-the-american-society-of-clinical-oncology-asco-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ono-pharma-announces-an-oral-presentation-on-phase-2-data-for-tirabrutinib-and-a-poster-session-on-ono-4578-ep4-antagonist-at-the-american-society-of-clinical-oncology-asco-annual-meeting\\\/\",\"name\":\"Ono Pharma Announces an Oral Presentation on Phase 2 Data for Tirabrutinib and a Poster Session on ONO-4578 (EP4 Antagonist) at the American Society of Clinical Oncology (ASCO) Annual Meeting - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ono-pharma-announces-an-oral-presentation-on-phase-2-data-for-tirabrutinib-and-a-poster-session-on-ono-4578-ep4-antagonist-at-the-american-society-of-clinical-oncology-asco-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ono-pharma-announces-an-oral-presentation-on-phase-2-data-for-tirabrutinib-and-a-poster-session-on-ono-4578-ep4-antagonist-at-the-american-society-of-clinical-oncology-asco-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250423948442\\\/en\\\/2406587\\\/22\\\/ONO_Logo.jpg\",\"datePublished\":\"2025-04-24T02:06:15+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ono-pharma-announces-an-oral-presentation-on-phase-2-data-for-tirabrutinib-and-a-poster-session-on-ono-4578-ep4-antagonist-at-the-american-society-of-clinical-oncology-asco-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ono-pharma-announces-an-oral-presentation-on-phase-2-data-for-tirabrutinib-and-a-poster-session-on-ono-4578-ep4-antagonist-at-the-american-society-of-clinical-oncology-asco-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ono-pharma-announces-an-oral-presentation-on-phase-2-data-for-tirabrutinib-and-a-poster-session-on-ono-4578-ep4-antagonist-at-the-american-society-of-clinical-oncology-asco-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250423948442\\\/en\\\/2406587\\\/22\\\/ONO_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250423948442\\\/en\\\/2406587\\\/22\\\/ONO_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ono-pharma-announces-an-oral-presentation-on-phase-2-data-for-tirabrutinib-and-a-poster-session-on-ono-4578-ep4-antagonist-at-the-american-society-of-clinical-oncology-asco-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ono Pharma Announces an Oral Presentation on Phase 2 Data for Tirabrutinib and a Poster Session on ONO-4578 (EP4 Antagonist) at the American Society of Clinical Oncology (ASCO) Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ono Pharma Announces an Oral Presentation on Phase 2 Data for Tirabrutinib and a Poster Session on ONO-4578 (EP4 Antagonist) at the American Society of Clinical Oncology (ASCO) Annual Meeting - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/ono-pharma-announces-an-oral-presentation-on-phase-2-data-for-tirabrutinib-and-a-poster-session-on-ono-4578-ep4-antagonist-at-the-american-society-of-clinical-oncology-asco-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Ono Pharma Announces an Oral Presentation on Phase 2 Data for Tirabrutinib and a Poster Session on ONO-4578 (EP4 Antagonist) at the American Society of Clinical Oncology (ASCO) Annual Meeting - Pharma Trend","og_description":"Positive data from the Phase 2 PROSPECT Study of tirabrutinib in U.S. patients with relapsed or refractory primary central nervous system lymphoma (PCNSL) will be presented in a rapid oral session. Data on the neoadjuvant ONO-4578 (EP4 antagonist) in combination with nivolumab for rectal cancer will be presented in a poster session. OSAKA, Japan&#8211;(BUSINESS WIRE)&#8211;Ono ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/ono-pharma-announces-an-oral-presentation-on-phase-2-data-for-tirabrutinib-and-a-poster-session-on-ono-4578-ep4-antagonist-at-the-american-society-of-clinical-oncology-asco-annual-meeting\/","og_site_name":"Pharma Trend","article_published_time":"2025-04-24T02:06:15+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250423948442\/en\/2406587\/22\/ONO_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/ono-pharma-announces-an-oral-presentation-on-phase-2-data-for-tirabrutinib-and-a-poster-session-on-ono-4578-ep4-antagonist-at-the-american-society-of-clinical-oncology-asco-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/ono-pharma-announces-an-oral-presentation-on-phase-2-data-for-tirabrutinib-and-a-poster-session-on-ono-4578-ep4-antagonist-at-the-american-society-of-clinical-oncology-asco-annual-meeting\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Ono Pharma Announces an Oral Presentation on Phase 2 Data for Tirabrutinib and a Poster Session on ONO-4578 (EP4 Antagonist) at the American Society of Clinical Oncology (ASCO) Annual Meeting","datePublished":"2025-04-24T02:06:15+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/ono-pharma-announces-an-oral-presentation-on-phase-2-data-for-tirabrutinib-and-a-poster-session-on-ono-4578-ep4-antagonist-at-the-american-society-of-clinical-oncology-asco-annual-meeting\/"},"wordCount":465,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/ono-pharma-announces-an-oral-presentation-on-phase-2-data-for-tirabrutinib-and-a-poster-session-on-ono-4578-ep4-antagonist-at-the-american-society-of-clinical-oncology-asco-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250423948442\/en\/2406587\/22\/ONO_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/ono-pharma-announces-an-oral-presentation-on-phase-2-data-for-tirabrutinib-and-a-poster-session-on-ono-4578-ep4-antagonist-at-the-american-society-of-clinical-oncology-asco-annual-meeting\/","url":"https:\/\/pharma-trend.com\/en\/ono-pharma-announces-an-oral-presentation-on-phase-2-data-for-tirabrutinib-and-a-poster-session-on-ono-4578-ep4-antagonist-at-the-american-society-of-clinical-oncology-asco-annual-meeting\/","name":"Ono Pharma Announces an Oral Presentation on Phase 2 Data for Tirabrutinib and a Poster Session on ONO-4578 (EP4 Antagonist) at the American Society of Clinical Oncology (ASCO) Annual Meeting - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/ono-pharma-announces-an-oral-presentation-on-phase-2-data-for-tirabrutinib-and-a-poster-session-on-ono-4578-ep4-antagonist-at-the-american-society-of-clinical-oncology-asco-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/ono-pharma-announces-an-oral-presentation-on-phase-2-data-for-tirabrutinib-and-a-poster-session-on-ono-4578-ep4-antagonist-at-the-american-society-of-clinical-oncology-asco-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250423948442\/en\/2406587\/22\/ONO_Logo.jpg","datePublished":"2025-04-24T02:06:15+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/ono-pharma-announces-an-oral-presentation-on-phase-2-data-for-tirabrutinib-and-a-poster-session-on-ono-4578-ep4-antagonist-at-the-american-society-of-clinical-oncology-asco-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/ono-pharma-announces-an-oral-presentation-on-phase-2-data-for-tirabrutinib-and-a-poster-session-on-ono-4578-ep4-antagonist-at-the-american-society-of-clinical-oncology-asco-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/ono-pharma-announces-an-oral-presentation-on-phase-2-data-for-tirabrutinib-and-a-poster-session-on-ono-4578-ep4-antagonist-at-the-american-society-of-clinical-oncology-asco-annual-meeting\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250423948442\/en\/2406587\/22\/ONO_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250423948442\/en\/2406587\/22\/ONO_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/ono-pharma-announces-an-oral-presentation-on-phase-2-data-for-tirabrutinib-and-a-poster-session-on-ono-4578-ep4-antagonist-at-the-american-society-of-clinical-oncology-asco-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Ono Pharma Announces an Oral Presentation on Phase 2 Data for Tirabrutinib and a Poster Session on ONO-4578 (EP4 Antagonist) at the American Society of Clinical Oncology (ASCO) Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61140","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=61140"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61140\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=61140"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=61140"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=61140"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}